Clarisse Marcombes

Clarisse Marcombes

Auto-generated profile, based on publicly available information

Clarisse Marcombes

Dermatology Department, AP-HP, Henri Mondor Hospital, Créteil, France; Reference Center for Auto-Immune Bullous Dermatoses, MALIBUL, AP-HP, Henri-Mondor Hospital, Créteil, France

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 August 2023 in Journal of the European Academy of Dermatology and Venereology
Verified
Journal Article
Closed access
CMC. Marcombes
C. Marcombes
SIS. Ingen‐Housz‐Oro
S. Ingen‐Housz‐Oro
FDFREDERIC DEZOTEUX
FREDERIC DEZOTEUX
DSD. Staumont‐Sallé
D. Staumont‐Sallé
BMB. Milpied
B. Milpied
VDV. Descamps
V. Descamps

21 July 2023 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
CMClarisse Marcombes
Clarisse Marcombes
LPLaetitia Penso
Laetitia Penso
AWAlain Weill
Alain Weill
RDRosemary Dray-Spira
Rosemary Dray-Spira
MZMahmoud Zureik
Mahmoud Zureik
ESEmilie Sbidian
Emilie Sbidian
Background: Many biologics are available for psoriasis and have been compared in real-life studies based on their persistence (i.e. time between initiation and discontinuation). However, after first-line biologic failure, data are lacking on the choice of second-line biologic among the four available classes [tumour necrosis factor inhibitors (TNFi); interleukin (IL)-12/IL-23 inhibitor (IL-12/IL-23i); IL-17 inhibitors (IL-17i); and IL-23 inhibitors (IL-23i)]. Objectives: To compare the long-term persistence of available second-line biologics in psoriasis according to prior exposure. Methods: This nationwide cohort study involved the administrative healthcare database of the French health insurance scheme linked to a hospital discharge database. Participants were adults with psoriasis, defined as having at least two prescriptions of a topical vitamin D derivative within a 2-year period, with initiation of a second-line biologic between 1 January 2015 and 31 December 2021. We included patients who initiated a second-line biologic directly after first-line discontinuation (i.e. without a ‘washout’ period). The end of follow-up was 30 June 2022. Discontinuation was defined as > 90 days without filling a prescription for the same treatment after the period covered by the previous prescription. Comparison of persistence by biologic class involved using propensity score-weighted Cox models (inverse probability treatment weighting) and adjustment of specific systemic nonbiologics (time-dependent variables). Results: We included 8693 patients [mean (SD) age 50 (14) years; 50.5% male]; 2824 (32.5%) started TNFi, 1561 (18.0%) IL-12/IL-23i, 2707 (31.1%) IL-17i and 1601 (18.4%) IL-23i. Overall, 1- and 3-year persistence rates were 60% and 30%, respectively. After weighting and adjustment, persistence was longer with IL-12/IL-23i [weighted hazard ratio (HRw) 0.68, 95% confidence interval (CI) 0.62–0.76)], IL-17i (HRw 0.70, 95% CI 0.64–0.78) and IL-23i (HRw 0.36, 95% CI 0.31–0.42) than TNFi, except after first-line IL-17i treatment, with no difference between IL-12/IL-23i, IL-17i and TNFi second-line persistence. Persistence was longer with IL-23i as a second-line treatment than IL-12/IL-23i (HRw 0.53, 95% CI 0.44–0.63) and IL-17i (HRw 0.51, 95% CI 0.44–0.60), regardless of first-line treatment, with no difference seen between IL-12/IL-23i and IL-17i (HRw 0.97, 95% CI 0.87–1.09). Conclusions: This real-life study suggests the longer persistence of IL-23i than TNFi, IL-17i and IL-12/IL-23i as second-line treatment for psoriasis. Persistence rates for all biologics remained low at 3 years.

28 March 2023 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
CMClarisse Marcombes
Clarisse Marcombes
LPLaetitia Penso
Laetitia Penso
ESEmilie Sbidian
Emilie Sbidian

1 May 2025 in Contact Dermatitis
Verified
Journal Article
Closed access
CMClarisse Marcombes
Clarisse Marcombes
KHKamar Bel Hareth
Kamar Bel Hareth
HMHéloïse Mazoyer
Héloïse Mazoyer
SSSabina Solinas
Sabina Solinas
SISaskia Ingen‐Housz‐Oro
Saskia Ingen‐Housz‐Oro
HAHaudrey Assier
Haudrey Assier

26 February 2026 in Annales de Dermatologie et de Vénéréologie
Verified
Journal Article
Closed access
BMB. Mouton
B. Mouton
SIS. Ingen-Housz-Oro
S. Ingen-Housz-Oro
BPB. Papouin
B. Papouin
CMC. Marcombes
C. Marcombes